IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0898105
(2001-07-03)
|
| 우선권정보 |
GB-19950023019 (1995-11-09); GB-19960001929 (1996-01-31); GB-19970009900 (1997-05-15) |
|
발명자
/ 주소 |
- Jones, David Hugh
- Farrar, Graham Henry
- Clegg, James Christopher Stephen
|
| 출원인 / 주소 |
- Microbiological Research Authority
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
2 인용 특허 :
78 |
초록
▼
A method of making a microparticle that contains DNA coding for a polypeptide is described in which a solvent extraction method is used and solvent extraction takes place at elevated temperature. Oral administration of the microparticle leads to its expression. DNA coding for an immunogen is for sti
A method of making a microparticle that contains DNA coding for a polypeptide is described in which a solvent extraction method is used and solvent extraction takes place at elevated temperature. Oral administration of the microparticle leads to its expression. DNA coding for an immunogen is for stimulating antibody formation in a recipient and DNA coding for a non-immunogenic polypeptide is for gene therapy applications. DNA is incorporated into the microparticle without destruction of its function.
대표청구항
▼
1. A composition comprising a polymer microparticle and an aqueous solution of DNA, wherein the DNA comprises a coding sequence, wherein the microparticle is 10 &mgr;m or less in diameter, and wherein the aqueous solution of DNA has an alcohol content of 1 to 40% and is encapsulated inside the micro
1. A composition comprising a polymer microparticle and an aqueous solution of DNA, wherein the DNA comprises a coding sequence, wherein the microparticle is 10 &mgr;m or less in diameter, and wherein the aqueous solution of DNA has an alcohol content of 1 to 40% and is encapsulated inside the microparticle. 2. The composition according to claim 1, wherein the microparticle comprises a biodegradable polymer.3. The composition according to claim 2, wherein the polymer is selected from the group consisting of a lactide-containing polymer, a glycolide-containing polymer and a polymer comprising lactide and glycolide.4. The composition according to claim 2, wherein the polymer is soluble in an organic solvent.5. The composition according to claim 1, wherein the microparticle consists of a biodegradable polymer.6. The composition according to claim 5, wherein the polymer is selected from the group consisting of a lactide-containing polymer, a glycolide-containing polymer and a polymer comprising lactide and glycolide.7. The composition according to claim 1, wherein the microparticle is in the size range 0.1 &mgr;m to 10 &mgr;m.8. The composition according to claim 1, wherein the DNA is circular DNA or plasmid DNA.9. The composition according to claim 1, wherein the DNA further comprises a promoter sequence operably linked to the coding sequence.10. The composition according to claim 9, wherein the coding sequence encodes an immunogen.11. The composition according to claim 10, wherein the coding sequence encodes an immunogenic component of a pathogenic organism selected from the group consisting of pathogenic bacteria and pathogenic viruses.12. A pharmaceutical composition comprising a plurality of polymer microparticles and a pharmaceutically acceptable carrier, wherein the microparticles contain an aqueous solution of DNA the aqueous solution of DNA has an alcohol content of 1 to 40%, and the DNA comprises a coding sequence encoding a polypeptide selected from the group consisting of: (a) the antigens FHA, PT, 68 kd-Pertacin, tetanus toxin, gp-48, NS1, Capsid, gp350, NS3, SA, I, NP E, M, gp340, F, H, HN, 35 kd protein, VP1, E1, E2, C, M, E and MSHA; and (b) immunogenic fragments, of the polypeptides of (a). 13. The composition according to claim 12 wherein the microparticles are in the size range 0.1 &mgr;m to 10 &mgr;m.14. The composition according to claim 13, wherein the DNA comprises double stranded plasmid DNA.15. The composition according to claim 14, wherein the DNA further comprises a promoter sequence operably linked to the coding sequence.16. The composition according to claim 12, wherein the polymer is a lactide containing polymer.17. The composition according to claim 12, wherein the polymer is a glycolide-containing polymer.18. The composition according to claim 12, wherein the polymer comprises poly(DL-lactide-co-glycolide).19. The composition according to claim 12 wherein at least 50% of the microparticles are in the size range 0.1 &mgr;m to 10 &mgr;m.20. The composition according to claim 12, further comprising a taste-enhancing agent.21. The composition of claim 1, wherein the alcohol is a straight chain or branched C2-C10alcohol.22. The composition of claim 1, wherein the alcohol is ethanol.23. The composition of claim 1, wherein the alcohol is methanol or propanol.24. The pharmaceutical composition of claim 12, wherein the alcohol is a straight chain or branched C2-C10alcohol.25. The pharmaceutical composition of claim 12, wherein the alcohol is ethanol.26. The pharmaceutical composition of claim 12, wherein the alcohol is methanol or propanol.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.